153 related articles for article (PubMed ID: 21856550)
1. Bortezomib-induced tumor lysis syndrome in a patient with HIV-negative plasmablastic lymphoma.
Lipstein M; O'Connor O; Montanari F; Paoluzzi L; Bongero D; Bhagat G
Clin Lymphoma Myeloma Leuk; 2010 Oct; 10(5):E43-6. PubMed ID: 21856550
[TBL] [Abstract][Full Text] [Related]
2. Plasmablastic haemato-lymphoid neoplasm with a complex genetic signature of Burkitt lymphoma responding to bortezomib.
Dasanu CA; Bauer F; Codreanu I; Padmanabhan P; Rampurwala M
Hematol Oncol; 2013 Sep; 31(3):164-6. PubMed ID: 22899491
[TBL] [Abstract][Full Text] [Related]
3. Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia.
Jaskiewicz AD; Herrington JD; Wong L
Pharmacotherapy; 2005 Dec; 25(12):1820-5. PubMed ID: 16305302
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib in plasmablastic lymphoma: a case report and review of the literature.
Saba NS; Dang D; Saba J; Cao C; Janbain M; Maalouf B; Safah H
Onkologie; 2013; 36(5):287-91. PubMed ID: 23689224
[TBL] [Abstract][Full Text] [Related]
5. Rapid progression of anemia related to tumor-lysis syndrome associated with bortezomib treatment in myeloma patients.
Suzuki K; Terui Y; Nishimura N; Ueda K; Mishima Y; Sakajiri S; Yokoyama M; Aiba K; Hatake K
Jpn J Clin Oncol; 2014 May; 44(5):435-41. PubMed ID: 24664944
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib-induced tumor lysis syndrome in multiple myeloma.
Sezer O; Vesole DH; Singhal S; Richardson P; Stadtmauer E; Jakob C; Boral AL; Esseltine DL; Mehta J
Clin Lymphoma Myeloma; 2006 Nov; 7(3):233-5. PubMed ID: 17229340
[TBL] [Abstract][Full Text] [Related]
7. Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration.
Terpos E; Politou M; Rahemtulla A
J Cancer Res Clin Oncol; 2004 Oct; 130(10):623-5. PubMed ID: 15449188
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma.
Castillo JJ; Reagan JL; Sikov WM; Winer ES
Br J Haematol; 2015 May; 169(3):352-5. PubMed ID: 25612847
[TBL] [Abstract][Full Text] [Related]
9. Tumor lysis syndrome early after treatment with bortezomib for multiple myeloma.
Kenealy MK; Prince HM; Hönemann D
Pharmacotherapy; 2006 Aug; 26(8):1205-6; discussion 1206. PubMed ID: 16863501
[No Abstract] [Full Text] [Related]
10. [Bortezomib-induced tumor lysis syndrome with a remarkable elevation of LDH in a case of relapsed and therapy-resistant multiple myeloma].
Arai A; Oshikawa G; Kurosu T; Miki T; Tohda S; Koyama T; Murakami N; Miura O
Rinsho Ketsueki; 2006 Aug; 47(8):777-80. PubMed ID: 16986718
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib-associated tumor lysis syndrome in multiple myeloma.
Furtado M; Rule S
Leuk Lymphoma; 2008 Dec; 49(12):2380-2. PubMed ID: 19052991
[No Abstract] [Full Text] [Related]
12. Acute pancreatitis caused by bortezomib.
Solakoglu T; Akyol P; Guney T; Dilek I; Atalay R; Koseoglu H; Akin E; Demirezer Bolat A; Buyukasik NS; Ersoy O
Pancreatology; 2013; 13(2):189-90. PubMed ID: 23561979
[TBL] [Abstract][Full Text] [Related]
13. Use of bortezomib in B-cell non-Hodgkin's lymphoma.
Wang M; Zhou Y; Zhang L; Nguyen CA; Romaguera J
Expert Rev Anticancer Ther; 2006 Jul; 6(7):983-91. PubMed ID: 16831071
[TBL] [Abstract][Full Text] [Related]
14. [Multiple myeloma complicated with disseminated zygomycosis after bortezomib therapy].
Nakamura S; Yata K; Jinno T; Harada T; Fujii S; Miki H; Nakano A; Kagawa K; Takeuchi K; Ozaki S; Abe M; Matsumoto T
Rinsho Ketsueki; 2010 Aug; 51(8):690-5. PubMed ID: 20805677
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib-induced Sweet syndrome.
Knoops L; Jacquemain A; Tennstedt D; Theate I; Ferrant A; Van den Neste E
Br J Haematol; 2005 Oct; 131(2):142. PubMed ID: 16197442
[No Abstract] [Full Text] [Related]
16. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.
Goy A; Younes A; McLaughlin P; Pro B; Romaguera JE; Hagemeister F; Fayad L; Dang NH; Samaniego F; Wang M; Broglio K; Samuels B; Gilles F; Sarris AH; Hart S; Trehu E; Schenkein D; Cabanillas F; Rodriguez AM
J Clin Oncol; 2005 Feb; 23(4):667-75. PubMed ID: 15613697
[TBL] [Abstract][Full Text] [Related]
17. Hyperlipidemia in a myeloma patient after bortezomib treatment.
Gozzetti A; Fabbri A; Defina M; Chitarrelli I; Bocchia M
Leuk Res; 2010 Sep; 34(9):e250. PubMed ID: 20363499
[No Abstract] [Full Text] [Related]
18. Optimizing bortezomib treatment in patients with relapsed multiple myeloma.
Richardson P
Clin Adv Hematol Oncol; 2006 May; 4(5):4-5; discussion 8; suppl 13. PubMed ID: 16832859
[No Abstract] [Full Text] [Related]
19. Bortezomib and bilateral herpes zoster.
di Meo N; Bergamo S; Dondas A; Trevisan G
Acta Dermatovenerol Alp Pannonica Adriat; 2012; 21(1):21-2. PubMed ID: 22584902
[TBL] [Abstract][Full Text] [Related]
20. Sweet-like syndrome induced by bortezomib.
Kolb-Mäurer A; Kneitz H; Goebeler M
J Dtsch Dermatol Ges; 2013 Dec; 11(12):1200-2. PubMed ID: 23905772
[No Abstract] [Full Text] [Related]
[Next] [New Search]
